Current clinical trials
Treatment trials as of March 2026:
| Name of Study | Open Since |
|---|---|
| Multiple Sclerosis | |
| An Open-label, Multicenter Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients with Relapsing Multiple Sclerosis Receiving Treatment with Ocrelizumab | 2020 |
| An Observational Study of Ocrelizumab-Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies | 2020 |
| An Open-label, Single arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects with Relapsing Multiple Sclerosis | 2019 |
| A Phase III Multicenter, Randomized Double-blind, Double-dummy, Parallel-grouop Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis. | 2022 |
| Seizure | |
| New-onset Refractory Status Epilepticus (NORSE) | 2020 |
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures | 2025 |
| A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | 2024 |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures | 2024 |
| Myasthenia Gravis | |
| A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Mild to Severe Generalized Myasthenia Gravis | 2025 |
| A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-label Remibrutinib | 2024 |
| Epilepsy | |
| SAFETY AND THERAPEUTIC MEASURES OF TRANSCRANIAL CATHODAL DIRECT CURRENT STIMULATION (TDCS) IN PATIENTS WITH REFRACTORY FOCAL EPILEPSY | 2023 |
| An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants with Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | 2024 |
| A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy | 2024 |
| Neuromyelitis Optica | |
| A long-term, open-label, low-interventional safety study of inebilizumab in the treatment of NMOSD (N-MOmentum LT) | 2024 |
| Stroke | |
| Efficacy and Safety of Milvexian Oral Drug on Stroke Patients | 2024 |
| CIPD | |
| A Phase 2b, Multi-center, Randomized, Double-blind, Placebocontrolled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 2025 |